Pacgen Life Science Corporation disclosed that its licensing partner, General Biologicals Corporation ("GBC") has announced acceptance of abstract entitled "P113-derived peptides as novel inhibitors for drug resistant Candida spp" at the 6th Congress of European Microbiologist held in Maastricht, Netherlands. The abstract highlights findings of a research study conducted by Institute of Molecular and Cellular Biology and Department of Life Sciences of National Tsing Hua University, Taiwan in collaboration with GBC. The company also disclosed that GBC has launched non-prescription over-the-counter products containing PAC-113 in Taiwan including cosmetic skin-care products, oral hygiene products and intimate hygiene products.

These non-prescription OTC products can be purchased on-line at www.p113lab.com and several local stores in Taiwan. GBC plans to formally launch these products through its existing global distribution channels in July 2015.